Articles Tagged With:
-
Is It Right to Screen All Adults for Illicit Drug Use?
Primary care clinicians should screen all adults for illicit drug use, including nonmedical prescription drug use, according to a draft recommendation from the U.S. Preventive Services Task Force.
-
New Guidance Targets Informed Consent for Stem Cell Therapies
Patients need to understand what is offered, whether a governmental authority has asserted its legislative right to regulate, and whether the intervention has complied with all applicable regulations.
-
Ethical Concerns if Opioids are Given in ED
Medicaid recipients are at moderate risk for conversion to opioid misuse after just one new prescription issued in the ED, according to the authors of a recent study.
-
ICU Team Members’ Ethics Knowledge Varies Widely
ICU team members may lack a common language to talk about ethical problems. These differences shape how ICU professionals think about an ethical dilemma — or even whether something is viewed as an ethical dilemma at all.
-
Cardiac Arrest in Takotsubo Syndrome
Investigators sought to determine whether secondary prevention interventions could reduce the mortality rate of takotsubo patients with cardiac arrest.
-
Safety of Carvedilol for Cocaine Users
The use of beta-blockers in cocaine users is controversial, and there are few data on their use in cocaine-associated heart failure. This prospective, observational, registry study of cocaine-associated heart failure patients showed that carvedilol is safe and effective in such patients.
-
Planning Therapy for Severe Tricuspid Regurgitation
A retrospective study of moderate to severe secondary tricuspid valve regurgitation showed that right ventricular systolic dysfunction (but not dilatation alone) is predictive of all-cause mortality.
-
Predicting Chemotherapy Cardiotoxicity
Administering trastuzumab after a course of anthracycline therapy for breast cancer can result in cardiac toxicity. Serial echocardiograms in this study showed that a lower initial left ventricular ejection fraction before anthracycline therapy and the amount of decrease in ejection fraction after the anthracycline course are predictive of subsequent trastuzumab cardiac toxicity.
-
When and How to Stop Dual Antiplatelet Therapy After PCI
Among patients with high-risk percutaneous coronary intervention who had completed three months of dual antiplatelet therapy with ticagrelor, patients who were randomized to ticagrelor alone experienced similar ischemic outcomes and a lower risk of bleeding at one year compared with those maintained on ticagrelor and aspirin.
-
Blood Pressure and Brain Lesions: Is There a Connection?
Reducing blood pressure in elderly patients could lower risk for development of lesions.